GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioRestorative Therapies Inc (NAS:BRTX) » Definitions » Cyclically Adjusted PS Ratio

BRTX (BioRestorative Therapies) Cyclically Adjusted PS Ratio : 0.02 (As of May. 29, 2025)


View and export this data going back to 2021. Start your Free Trial

What is BioRestorative Therapies Cyclically Adjusted PS Ratio?

As of today (2025-05-29), BioRestorative Therapies's current share price is $1.78. BioRestorative Therapies's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was $81.80. BioRestorative Therapies's Cyclically Adjusted PS Ratio for today is 0.02.

The historical rank and industry rank for BioRestorative Therapies's Cyclically Adjusted PS Ratio or its related term are showing as below:

BRTX' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.01   Med: 0.02   Max: 0.72
Current: 0.02

During the past years, BioRestorative Therapies's highest Cyclically Adjusted PS Ratio was 0.72. The lowest was 0.01. And the median was 0.02.

BRTX's Cyclically Adjusted PS Ratio is ranked better than
99.6% of 497 companies
in the Biotechnology industry
Industry Median: 5.33 vs BRTX: 0.02

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

BioRestorative Therapies's adjusted revenue per share data for the three months ended in Mar. 2025 was $0.003. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $81.80 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


BioRestorative Therapies Cyclically Adjusted PS Ratio Historical Data

The historical data trend for BioRestorative Therapies's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioRestorative Therapies Cyclically Adjusted PS Ratio Chart

BioRestorative Therapies Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.15 0.03 0.02 0.01 0.01

BioRestorative Therapies Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.02

Competitive Comparison of BioRestorative Therapies's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, BioRestorative Therapies's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioRestorative Therapies's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioRestorative Therapies's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where BioRestorative Therapies's Cyclically Adjusted PS Ratio falls into.


;
;

BioRestorative Therapies Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

BioRestorative Therapies's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=1.78/81.80
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioRestorative Therapies's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, BioRestorative Therapies's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.003/134.9266*134.9266
=0.003

Current CPI (Mar. 2025) = 134.9266.

BioRestorative Therapies Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 149.000 100.684 199.675
201509 96.000 100.392 129.024
201512 199.000 99.792 269.063
201603 9.000 100.470 12.087
201606 16.000 101.688 21.230
201609 5.000 101.861 6.623
201612 6.000 101.863 7.948
201703 7.000 102.862 9.182
201706 20.000 103.349 26.111
201709 16.000 104.136 20.731
201712 19.000 104.011 24.647
201803 9.500 105.290 12.174
201806 18.500 106.317 23.478
201809 13.000 106.507 16.469
201812 9.667 105.998 12.305
201903 7.250 107.251 9.121
201906 6.200 108.070 7.741
201909 6.333 108.329 7.888
201912 1.684 108.420 2.096
202003 0.065 108.902 0.081
202006 0.048 108.767 0.060
202009 0.038 109.815 0.047
202012 0.024 109.897 0.029
202103 0.023 111.754 0.028
202106 0.018 114.631 0.021
202109 0.009 115.734 0.010
202112 0.001 117.630 0.001
202203 0.005 121.301 0.006
202206 0.020 125.017 0.022
202209 0.008 125.227 0.009
202212 0.001 125.222 0.001
202303 0.008 127.348 0.008
202306 0.017 128.729 0.018
202309 0.003 129.860 0.003
202312 0.004 129.419 0.004
202403 0.005 131.776 0.005
202406 0.011 132.554 0.011
202409 0.029 133.029 0.029
202412 0.005 133.157 0.005
202503 0.003 134.927 0.003

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


BioRestorative Therapies  (NAS:BRTX) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


BioRestorative Therapies Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of BioRestorative Therapies's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BioRestorative Therapies Business Description

Traded in Other Exchanges
Address
40 Marcus Drive, Suite One, Melville, NY, USA, 11747
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
Executives
Dale Broadrick 10 percent owner 3003 BRICK CHURCH PIKE, NASHVILLE TN 37207
Francisco Silva director, 10 percent owner, officer: VP of Research and Development STEM CELL ASSURANCE, INC., 555 HERITAGE DRIVE, JUPITER FL 33458
Lance Alstodt director, 10 percent owner, officer: President, CEO, COB BIORESTORATIVE THERAPIES, INC., 40 MARCUS DRIVE, SUITE 1, MELVILLE NY 11747
Robert Eugene Kristal officer: Chief Financial Officer 4719 COLE AVENUE, DALLAS TX 75205
Patrick F. Williams director C/O ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD, SUITE 100, PLEASANTON CA 94588
David A Rosa director 10901 RED CIRCLE DRIVE, SUITE 150, MINNETONKA MN 55343
Nickolay V. Kukekov director 4524 WESTWAY AVE, DALLAS TX 75205
Mark Weinreb director, 10 percent owner, officer: CEO and Chairman of the Board STEM CELL ASSURANCE, INC., 555 HERITAGE DRIVE, JUPITER FL 33458
Paul Jude Tonna director 69 CHICHESTER ROAD, HUNTINGTON NY 11743
A. Jeffrey Radov director 8 WALWORTH AVENUE, SCARSDALE NY 10583
Robert Paccasassi officer: VP, Quality and Compliance C/O BIORESTORATIVE THERAPIES, INC., 40 MARCUS DRIVE, SUITE 1, MELVILLE NY 11747
Robert B Catell director 62 OSBORNE ROAD, GARDEN CITY NY 11530
Adam D. Bergstein officer: SVP, Planning and Business Dev 167 HAZEL AVENUE, GLENCOE IL 60022
John M Desmarais director 230 PARK AVENUE, NEW YORK NY 10169
Westbury Trust 10 percent owner VICTORIA HALL, 11 VICTORIA STREET, P.O. BOX HM 1065, HAMILTON D0 00000

BioRestorative Therapies Headlines

From GuruFocus